Journal of International Medical Research · 2019 · 30 citations · 10 references
MedicineHematologyOncologyAnatomic PathologyMolecular PathologyRenal PathologyAmyloid FormationAmyloidosis Of The KidneyProtein Aggregation DisordersRenal AmyloidosisRenal DiseaseSplenic PathologyAmyloid FibrilsBortezomib-based TherapyKidney Biopsy FindingsMisfolded Protein AggregationRisk-adapted TherapySplenic AmyloidosisSplenic BiopsySplenic Rupture
Amyloid light chain (AL) amyloidosis is a protein conformational disease. AL amyloidosis results from aggregation of misfolded proteins that are deposited in tissues as amyloid fibrils. Diagnosis of AL amyloidosis can be challenging due to its low incidence and clinical complexity. Therapy requires a risk-adapted approach involving dose reductions and schedule modifications of chemotherapy regimens along with close monitoring of hematologic and organ responses. We herein describe a patient whose condition was diagnosed as systemic AL amyloidosis and presented with splenic rupture as the initial symptom. Congo red staining of the kidney biopsy was positive. The normal structure of the liver and spleen had been replaced by amyloid deposition. The chemotherapy strategy involved a combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone.
10
Giovanni Palladini, Angela Dispenzieri, Morie A. Gertz et al. · Journal of Clinical Oncology · 2012 · 969 citations
Medicine, Cardiology, Hematology +17
Giovanni Palladini, Ute Hegenbart, Paolo Milani et al. · Blood · 2014 · 503 citations
Medicine, Nephrology, Oncology +15